Optima Capital’s Revolution Medicines RVMD Stock Holding History

Optima Capital’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$80	–	1059
2025 Q4	$80	Buy	+1	New	+$66	﹤0.01%	1376

Other funds holding RVMD

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Optima Capital's RVMD Position: Q1 2026 in Review

Optima Capital sold out of Revolution Medicines (RVMD) in Q1 2026, closing a stake of 1 share — an estimated $80 sold.

Optima Capital first reported a position in RVMD in Q4 2025 and held it in 1 quarter. The position peaked at $80 in Q4 2025. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

Optima Capital reported no remaining Revolution Medicines position as of Q1 2026 after selling out during the quarter.
Optima Capital sold 1 Revolution Medicines share in Q1 2026, an estimated $80.
Optima Capital first reported a position in Revolution Medicines in Q4 2025 and held it in 1 quarter.
Optima Capital's Revolution Medicines position peaked at $80 in Q4 2025.
512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Optima Capital's 13F filing for Q1 2026, filed 5 May 2026.